All News
#ACR21 2022 ACR/EULAR MPA Criteria
▶️Classification, NOT diagnostic!
⭐️Clinical: negative for nasal GPA symptoms
⭐️Lab: +6 for pANCA or MPO, negative for cANCA/PR3 or eosinophilia
@RheumNow https://t.co/6YWmabNzuH https://t.co/XVzBF2KONp
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 2022 ACR/EULAR Large Vessel Vasculitis Criteria:
🌎One reason for updating 31 year old criteria -> now an international effort that better reflects heterogeneous global disease
@RheumNow https://t.co/6YWmabNzuH https://t.co/YXm85uQZCK
Links:
Eric Dein ericdeinmd ( View Tweet)
ACR/EULAR Classification Criteria for Large Vessel Vasculitis (TAK/GCA), updated from prior to include imaging
Must emphasize typical disclaimers; these are for classification, not specifically for diagnosis
Great effort and useful result, esp for trials
#ACR21 @petercgrayson https://t.co/IYFyh5oYBT
Mike Putman EBRheum ( View Tweet)
#ACR21 2022 ACR/EULAR GCA Criteria
▶️Classification, NOT diagnostic!
⭐️Must be >50yo
⭐️Clinical, lab, imaging, and biopsy findings
+TA biopsy or Halo sign = 5 points, 6+ points needed for classification
@RheumNow https://t.co/6YWmabNzuH https://t.co/cZVrWA02U6
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
Janet Pope Janetbirdope ( View Tweet)
#ACR21 L19: TitAIN: Secukinumab for GCA
⭐️Phase 2 study with n=52
⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8%
⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g)
- Looking forward to larger study
@Rheumnow
https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg
Links:
Eric Dein ericdeinmd ( View Tweet)
IL-17i for GCA? TitAIN study met all endpoints!
phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB
👉effective sustained remission
👉longer time to GCA flare
👉lower dose of steroids by week 52
👉no increase in AEs
#ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
TheDaoIndex KDAO2011 ( View Tweet)
Secukinumab in GCA, phase 2 (TitAIN):
I can't deny this is promising, but phase 2 needs to be
interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def)
@drpnash: "Bring on the phase 3 trials"
(recruitment started👀)
#ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ
David Liew drdavidliew ( View Tweet)
ARIAA Study - Abatacept Reverses ACPA+ Subclinical Arthritis: Dr. Jack Cush discusses abstract #0455, a preclinical RA intervention trial - abatacept or placebo given to at risk individuals (arthralgias, CCP+, MRI+) for 6 months, presented at #ACR21.
https://t.co/fz1hPTleMn https://t.co/V4PsPZ0ZwF
Links:
Dr. John Cush RheumNow ( View Tweet)
Impressive case of vasculitis – should be part of @ACRheum image bank #ThievesMarket #ACR21 Abst#TM20 @rheumnow https://t.co/YiBikROuzb
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Despotovic shares general principles about ICU admissions in patients w/ #rheumatic disease.
🔺#SLE, RA, systemic #vasculitis, SSc, IIMs
🔺serologic testing useful but interpret w/n clinical context
@RheumNow #ACR21 https://t.co/jb3Mt31dZz
sheila RHEUMarampa ( View Tweet)
What is the effect of #avacopan on renal function in pts with #ANCA #vasculitis?
👉🏼Results from ADVOCATE show greater recovery of kidney function with avacopan vs steroids
👉🏼Particularly marked in pts with CKD4 and eGFR<60
Abs#L14 #ACR21 @RheumNow
https://t.co/5z7YulxVAj https://t.co/LnJr4gLuTV
Mrinalini Dey DrMiniDey ( View Tweet)
Avacopan effects on renal disease in AAV presented in further detail. Greater recovery with avacopan, which was accentuated in those with worse renal disease or proteinuria at baseline. Abstr#L14 #ACR21 @RheumNow https://t.co/dfTmhhsNnX
Richard Conway RichardPAConway ( View Tweet)
Avacopan (C5a inhibitor) is a new promising therapy for ANCA vasculitis. US FDA approved in Oct 2021
#ACR21 @rheumnow https://t.co/tWvKzHOT5V
swethaann23 swethaann23 ( View Tweet)
Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
Richard Conway RichardPAConway ( View Tweet)
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Dr. D.McGonagle on the patterns of dse ➡true #vasculitis vs. vasculitis mimics seen in skin of #COVID19 pts in this very informative slide
🔴Mild/no lung dse: vasc cuffing,⬆type1 IFN
🔴Severe dse: vasc occlusion,⬇type1 IFN
@RheumNow #ACR21 #MedTwitter
https://t.co/Y5S2k7LO1p https://t.co/puBJm4Kd8H
Links:
sheila RHEUMarampa ( View Tweet)
DCVAS testing results in GCA. @davidliew @philipcrobinson are you guys essentially not imaging anyone in anyway? What's going on? #ACR21 @RheumNow https://t.co/IMr5ee2Iea
Richard Conway RichardPAConway ( View Tweet)
Knowledge Bowl at #ACR21
⭐️In a suspected PAN case, you order a peripheral smear to look for this potential etiology,
➡️Hairy cells
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
